Prevalence of clinically relevant drug-drug interactions in patients enrolled in NCTN clinical trials.

• DOI: 10.1200/jco.2018.36.15_suppl.e18819
• Publication Date: 2018-09-05T14:42:18Z
• Authors: Lauren A Marcath; Taylor D Coe; Emily K Hoylman; Bruce G. Redman; Daniel Louis Hertz
• Keywords: Concomitant; Medical record

e18819 Background: Oncology patients are at high risk of clinically relevant drug-drug interactions (DDIs) due to rates polypharmacy. DDIs in enrolled clinical trials can adversely affect patient safety, study drug outcomes and validity. The objective was determine the prevalence involving drugs NCTN University Michigan Comprehensive Cancer Center (UMCCC). Methods: All commercially available medications UMCCC from January 2013 August 2017 were included. Patient’s concomitant medication lists enrollment date, or next collected electronic medical records. Medication screened using Lexicomp, all major/contraindicated (level D X) agents recorded. Flagged reviewed by a pharmacist PharmD student for relevance. Discordant decisions discussed until reaching consensus. A interaction defined as DDI that would warrant change ensure safety enrollment. Results: One hundred thirty 35 Patients taking 6.7 on average (median: 6, range: 0-21). Lexicomp detected least one level X 23.8% (31/130). Ten percent (13/130) had DDI, with 46.2% (6/13) affected efficacy agent. Conclusions: These findings confirm patents trials. More consistent stringent screening is needed during reduce enhance trial data Additionally, emphasis should be placed likely have such if strong inhibitors inducers CYP450 enzymes.